• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511

2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (CAS No. 1402166-06-6): A Versatile Building Block in Modern Medicinal Chemistry

2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (CAS No. 1402166-06-6) is a structurally unique compound that has emerged as a critical intermediate in the field of organic synthesis and pharmaceutical development. This molecule belongs to the class of boronic acid derivatives and features a 1,3,2-dioxaborolane ring system as a core structural motif. The 1,3,2-dioxaborolane ring is known for its exceptional stability and reactivity in transition-metal-catalyzed cross-coupling reactions, particularly in Suzuki-Miyaura couplings and Chan-Lam couplings. The piperidin-1-yl substituent attached to the pyridine ring introduces a flexible and bioactive pharmacophore, making this compound a promising candidate for medicinal applications.

Recent advancements in drug discovery have highlighted the importance of boronic acid derivatives as modular building blocks for the synthesis of biologically active molecules. The 1,3,2-dioxaborolane ring in 2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine ensures a balance between reactivity and stability, which is crucial for ligand design in medicinal chemistry. A study published in Journal of Medicinal Chemistry (2023) demonstrated that boronic acid derivatives with similar structural features have been effectively utilized in the development of tyrosine kinase inhibitors, a class of drugs that plays a pivotal role in the treatment of oncological disorders and inflammatory diseases.

The piperidin-1-yl group in 2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is a key structural element that contributes to the compound's hydrophobicity and stereochemical flexibility. These properties are particularly advantageous in the design of selective enzyme inhibitors and modulators of G-protein-coupled receptors (GPCRs), which are central to numerous therapeutic targets in modern medicine. Researchers at MIT have recently employed similar 1,3,2-dioxaborolane-based compounds in the development of novel anti-cancer agents with enhanced bioavailability and targeted delivery capabilities.

The 1,3,2-dioxaborolane ring system is a hallmark of organoborane chemistry, a field that has seen significant growth in recent years due to its applications in drug development and materials science. The 4,4,5,5-tetramethyl substituents on the dioxaborolane ring in 2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine enhance the stability of the boronic acid functionality, preventing premature hydrolysis under physiological conditions. This feature is particularly important in prodrug design, where the compound may serve as a precursor to more active pharmacophores upon metabolic activation.

Recent studies in organic synthesis have emphasized the role of 1,3,2-dioxaborolane rings in enabling mild reaction conditions for cross-coupling processes. The 2-(piperidin-1-yl)pyridine scaffold in 2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine provides a platform for the introduction of diverse functional groups, allowing for the parallel synthesis of library compounds in high-throughput screening campaigns. This approach has been instrumental in the discovery of novel lead compounds for neurodegenerative disorders and metabolic syndromes.

The CAS No. 1402166-06-6 designation for 2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine underscores its importance in the chemical registry and its potential for industrial scale-up. The molecule's modular architecture allows for the incorporation of bioisosteres and stereochemical variations, which are essential for structure-activity relationship (SAR) studies. A recent review in ACS Medicinal Chemistry Letters (2023) highlighted the 1,3,2-dioxaborolane ring as a privileged structure in the development of covalent inhibitors for targeted protein degradation and proteolysis-targeting chimeras (PROTACs).

Furthermore, the 1,3,2-dioxaborolane ring system in 2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine has been exploited in fluorescent labeling and molecular imaging applications. The piperidin-1-yl group can be functionalized with fluorophores or radioisotopes, enabling the compound to serve as a probe for in vivo imaging and diagnostic purposes. This dual functionality as both a synthetic intermediate and a biological probe positions CAS No. 1402166-06-6 as a versatile tool in translational research.

In conclusion, 2-(piperidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (CAS No. 1402166-06-6) exemplifies the convergence of organoborane chemistry and medicinal chemistry in the pursuit of innovative therapeutics. Its structural versatility, chemical stability, and pharmacological relevance make it a cornerstone in modern drug discovery efforts. As research in 1,3,2-dioxaborolane-based compounds continues to expand, the potential applications of CAS No. 1402166-06-6 are expected to grow significantly in both academic research and industrial development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)